Items Tagged ‘kisqali’

December 12th, 2017

Kisqali® Improves Outcomes of Premenopausal Women with HR+/HER2- Advanced Breast Cancer

By

It was announced today that results from the Phase III MONALEESA-7 trial evaluating Kisqali® (ribociclib) in combination endocrine-based therapy in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at the 2017 Annual San Antonio Breast Cancer […]

View full entry

Tags: advanced breast cancer, Breast Cancer, cyclin-dependent kinase, inhibitor, kisqali, MONELESSA 7, News, Precision Cancer Medicine, premenopausal, ribociclib, San Antonio Breast Cancer Symposium


November 14th, 2017

Kisqali® Improves Outcomes for Premenopausal Women with HR+/HER2- Advanced Breast Cancer

By

Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old.1,2 ,3 Historically there younger women were treated the same as their older counterparts, researchers however have more recently begun to focus on improving the treatment outcomes for […]

View full entry

Tags: advanced breast cancer, Breast Cancer, CDK4/6, cyclin-dependent kinase 4 and 6, kisqali, MONALEESA-7, News, Precision Cancer Medicine, ribociclib


March 16th, 2017

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer

By

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination benefits all such women and leads to improved survival without cancer recurrence. The interim results from a large clinical […]

View full entry

Tags: Breast Cancer, kisqali, Metastatic Breast Cancer, News, riboiclib, Stages II-III Breast Cancer